Entos Pharmaceuticals Inc. has been awarded a $4 million grant by California Institute for Regenerative Medicine (CIRM) to support the completion of IND-enabling activities with ENTLEP-001, a durable genetic medicine for the treatment of congenital generalized lipodystrophy.

Ymmunobio AG, in collaboration with the Paul Scherrer Institute, has received an Innosuisse grant to develop innovative radioactive loaded antibodies for the treatment and diagnosis of solid tumors based on Ymmunobio’s proprietary YB-800.

Kevirx Inc. has been awarded nearly $2 million in grant funding from the U.S. Department of Defense (DoD)’s peer-reviewed medical research program.

Lift Biosciences Ltd. has been awarded a grant of over £1 million (US$1.3 million) from Innovate UK that will fund a collaboration between Lift and researchers at the University of Cambridge.

Researchers at Washington University School of Medicine in St. Louis have received a $5 million grant from the Leukemia & Lymphoma Society (LLS) to support research aimed at developing new immunotherapies for different types of blood-based cancers.

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded US$ 2.2 million to Limmatech Biologics AG to advance the development of its novel vaccine candidate to prevent Neisseria gonorrhoeae infections.

Cantabio Pharmaceuticals Inc. has been awarded a grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support the development of a cell-penetrant DJ-1 protein replacement therapeutic candidate for the treatment of Parkinson’s disease.

Domain Therapeutics SA has been awarded a grant as part of the Hospital-University Research in Health (RHU) SPRINT consortium, which seeks to progress a precision medicine for cutaneous T-cell lymphoma (CTCL).

Factor Bioscience Inc. has been awarded a grant by the U.S. Department of Defense to develop next-generation cell therapy candidates using Factor's patented mRNA, cell-reprogramming, and gene-editing technologies.